AIM ImmunoTech is trading at $0.24 (-6.42%) after an intraday reversal following initial buying on its patent announcement.
- The company announced a broad U.S. patent covering Ampligen with pembrolizumab, extending oncology protection through December 20, 2039.
- Available reporting does not identify a specific negative company announcement behind the decline.
- The S&P 500 is down 0.54%, adding risk-off pressure, though broader markets alone do not fully explain the move.